Johannes Weirather
-
- Cardiac Fibrosis and Remodeling 7
- Immunology top 5%
-
- Lymphoma Diagnosis and Treatment 15
- Oncology top 5%
- CAR-T cell therapy research 11
- Peptidase Inhibition and Analysis 3
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research 12
-
- Signaling Pathways in Disease 6
- Protein Degradation and Inhibitors 4
-
- Monoclonal and Polyclonal Antibodies Research 5
- Co-authors
- Stefan FrantzUlrich HofmannNiklas BeyersdorfThomas KerkauGeorg ErtlAnna FreyBenjamin VogelGustavo C. Ramos
- Partner nations
- GermanyUnited StatesSpain
In The Last Decade
Johannes Weirather
28 papers receiving 1.8k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Cardiology and Cardiovascular Medicine 753
- Immunology 529
- Pathology and Forensic Medicine 425
- Oncology 509
- Genetics 191
Countries citing papers authored by Johannes Weirather
This map shows the geographic impact of Johannes Weirather's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Johannes Weirather with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Johannes Weirather more than expected).
Fields of papers citing papers by Johannes Weirather
This network shows the impact of papers produced by Johannes Weirather. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Johannes Weirather. The network helps show where Johannes Weirather may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Johannes Weirather, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 10 | |
| 2 | 2022 | 1 | |
| 3 | 2021 | 6 | |
| 4 | Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 studybreakdown → | 2020 | 324 |
| 5 | 2020 | 68 | |
| 6 | 2020 | 2 | |
| 7 | 2020 | 1 | |
| 8 | 2020 | 9 | |
| 9 | 2019 | 20 | |
| 10 | 2019 | 5 | |
| 11 | 2019 | 7 | |
| 12 | 2017 | 1 | |
| 13 | 2017 | 137 | |
| 14 | L-MIND: MOR208 combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R-R DLBCL) - a single-arm phase II study | 2017 | 1 |
| 15 | 2017 | 1 | |
| 16 | 2016 | 19 | |
| 17 | 2016 | 51 | |
| 18 | 2015 | 20 | |
| 19 | 2013 | 61 | |
| 20 | 2012 | 381 |
About Johannes Weirather
Johannes Weirather is a scholar working on Genetics, Pathology and Forensic Medicine and Oncology, having authored 28 papers that have together received 1.8k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (15 papers), Chronic Lymphocytic Leukemia Research (12 papers), CAR-T cell therapy research (11 papers), Cardiac Fibrosis and Remodeling (7 papers), Signaling Pathways in Disease (6 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Protein Degradation and Inhibitors (4 papers) and Peptidase Inhibition and Analysis (3 papers). The work is most often cited by research in Cardiology and Cardiovascular Medicine (753 citations), Immunology (529 citations) and Pathology and Forensic Medicine (425 citations). Johannes Weirather has collaborated with scholars based in Germany, United States and Spain. Frequent co-authors include Stefan Frantz, Ulrich Hofmann, Niklas Beyersdorf, Thomas Kerkau, Georg Ertl, Anna Frey, Benjamin Vogel, Gustavo C. Ramos, Johann Bauersachs and A. A. Podolskaya. Their work appears in journals such as Blood, Journal of Clinical Oncology, Circulation Research, Hematological Oncology and Circulation Heart Failure.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.